Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 353

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 353
---
 |   -6,975 | ​ | ​ | ​ | ​                                          | ​ |   — | ​ | ​ | ​ | ​                                 | ​ |   -6,975 | ​ | ​ |
| Balances as of June 30, 2024                                                                       | ​ | ​ | ​                                    | ​ |   3,963,910 | ​ | ​ | ​ | ​      | $ |  85,503 | ​ | ​ | ​ | ​ | ​           | ​ |   2,574,767 | ​ | ​ | ​ | ​      | $ |   2 | ​ | ​ | ​ | ​                        | $ |     944 | ​ | ​ | ​ | ​                  | $ |  -74,016 | ​ | ​ | ​ | ​                                          | $ |   — | ​ | ​ | ​ | ​                                 | $ |  -73,070 | ​ | ​ |

The accompanying notes are an integral part of these condensed consolidated financial statements. F-33

TABLE OF CONTENTS

TVARDI THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, amounts in thousands)

| ​                                                                           
 ​                                                                           
 Cash flows from operating activities:                                       | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | For the Six Months Ended June 30, 
 2025                              
 ​                                 | ​ |       ​ | ​ | ​ 
 ​ | ​ 
 ​ | 2024 
 ​    | ​ |       ​ | ​ | ​ 
 ​ 
 ​ |
|:----------------------------------------------------------------------------|:--|:--|:----------------------------------|:--|--------:|:--|:--|:--|:-----|:--|--------:|:--|:--|
| Net loss                                                                    | ​ | ​ | ​                                 | $ |  -5,412 | ​ | ​ | ​ | ​    | $ | -11,177 | ​ | ​ |
| Adjustments to reconcile net loss to net cash used in operating activities: | ​ | ​ | ​                                 | ​ |       ​ | ​ | ​ | ​ | ​    | ​ |       ​ | ​ | ​ |
| Depreciation and amortization expense                                       | ​ | ​ | ​                                 | ​ |      47 | ​ | ​ | ​ | ​    | ​ |      47 | ​ | ​ |
| Stock-based compensation expense                                            | ​ | ​